1. Home
  2. BCDA

BCDA

BioCardia Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 2:29pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Founded: N/A Country:
N/A
Employees: N/A City: SUNNYVALE
Market Cap: 9.7M IPO Year: N/A
Target Price: $4.00 AVG Volume (30 days): 357.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.55 EPS Growth: N/A
52 Week Low/High: $0.36 - $2.92 Next Earning Date: 01-01-0001
Revenue: $477,000 Revenue Growth: -64.72%
Revenue Growth (this year): -25.16% Revenue Growth (next year): 436.41%

Share on Social Networks: